« Previous | Next » | All Messages |  PHLI Message Board Home | recommend post |  Ignore Poster

PHLI News PacificHealth Laboratories Launches SATIATRIM(R), the First of a New Class of Weight Loss Products That Extends Satiety

MATAWAN, N.J.--(BUSINESS WIRE)--PacificHealth Laboratories, Inc. (OTCBB: PHLI), a nutrition technology company, announced today the launch of SATIATRIM, a new type of weight loss product that has been shown in multiple clinical trials to reduce caloric intake up to 20% and extend satiety for up to four hours following a meal. SATIATRIM uses a patented combination of nutritional ingredients to stimulate satiety regulatory proteins naturally found in the gut that control caloric intake and appetite. Additionally, SATIATRIM contains ingredients that are proven to increase the metabolism of fat.

Weight loss represents one of the largest consumer categories in the United States, with an estimated $50 billion plus spent in 2006 on products and services. According to government data, 141,000,000 American adults are now overweight and 31% are categorized as obese. It is estimated that 71,000,000 Americans are on some type of weight-loss program.

Dr. Robert Portman, CEO of PacificHealth Laboratories, said, “Products that extend satiety acting alone or as an additive to food have become a major area of focus for food and drug companies. The release of SATIATRIM is the culmination of a ten-year research effort by PacificHealth Laboratories. SATIATRIM is a great tasting beverage that is extremely effective in suppressing appetite and extending the feeling of fullness after a meal. In an open trial, consumers lost, on average, 2.5 pounds per week, which most obesity experts feel is the ideal rate of weight loss. The proprietary formula can also be incorporated into various types of foods and beverages to provide extended satiety.”

SATIATRIM is available as an 8-ounce ready-to-drink beverage in chocolate, vanilla and mixed berry flavors. The retail price is $39.95 for a case of 27 servings, or a one-week supply. SATIATRIM can only be purchased, at this time, at www.satiatrim.com. For a limited time, consumers can take advantage of a special introductory offer of one free case with each case of SATIATRIM purchased. There are no shipping charges. During the first two months the Company will be relying on paid Internet search to generate sales.

Dr. Portman continued, “Equally exciting is some of the initial data coming from our research collaboration with the University of Manchester in Manchester, England. Preliminary data shows that SATIATRIM reduces the movement of food through the stomach by up to 60% compared to a placebo and that subjects consuming SATIATRIM exhibited a significant drop in the volume of food they were able to consume. These results strongly suggest that, in addition to its value as a weight loss product, SATIATRIM may offer considerable benefits in treating Type 2 diabetes, the fastest growing chronic condition in the US.”

The SATIATRIM website (www.satiatrim.com) provides comprehensive information about the product, its use and the underlying science. It also has a number of unique interactive elements. Consumers are able to enter their current and target weights and find out how long it will take them to achieve their goal using the SATIATRIM Success Plan, a total lifestyle program combining diet, exercise, and SATIATRIM. Consumers who complete a free online registration may also track their weight-loss progress and develop their own weekly meal plan. The weekly meal planner, which offers hundreds of meal choices, including homemade recipes, prepared entrees and even fast food options, permits consumers to easily and conveniently control their daily calories without the annoyance of doing their own calorie counting or the expense of purchasing meals through a commercial plan. Adding SATIATRIM to a reduced calorie diet helps consumer feel satisfied even though they are eating less and keeps them hunger free between meals.

For more information about SATIATRIM, visit www.satiatrim.com

About PacificHealth Laboratories, Inc.:

PacificHealth Laboratories, Inc. (PHLI.OB), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI’s principle areas of focus include weight loss, management of Type 2 diabetes and sports performance. To learn more, visit www.pacifichealthlabs.com.

This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects", "plans", "will", "estimates", "forecasts", "projects" or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.